Start-Up Quarterly Statistics, Q3 2015
This article was originally published in Start Up
Start-ups raised $2.57 billion in Q3. Biopharma companies penned 23 alliances; 11 acquisitions were signed, none in the diagnostics industry.
You may also be interested in...
The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.
Deal Watch: Amgen Takes Center Stage With Trio Of Transactions
The big biotech enters a collaboration in cancer immunotherapy and inflammation with Xencor, acquires Dutch biotech Dezima, and licenses a c-MET inhibitor to NantWorks. Also, Sun Pharma steps in to buy InSite Vision, which had been targeted by QLT.
CETP Inhibitors Back In The Fold: Amgen Dives In With Dezima Buy
TA-8995 is potentially best-in-class and could fill a void in Amgen's portfolio for an oral agent, Exec VP R&D Sean Harper says in an interview. Development will focus on LDL-C lowering, not HDL-C increases.